Continuing the Conversation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Addressing Operational Challenges and Integrating New and Emerging Antibody-Based Regimens

This activity was originally broadcast live as a satellite symposium held in conjunction with HOPA 2023.

Program Description

The rapid development and approval of antibody-based treatments, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates, for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has posed several challenges for oncology pharmacists. Considerations for the effective and safe administration and implementation of antibody-based regimens in the treatment and management of R/R DLBCL will be discussed. Expert panelists will outline approaches for oncology pharmacists to integrate these emerging therapies into clinical practice and overcome operational challenges to facilitate access to novel antibody-based therapies in early lines of therapy for patients with R/R DLBCL. This program is a continuation of “Ushering in a New Era of Targeted Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Focus on New and Emerging Antibody-Based Regimens,” and will build upon clinical data and topics presented.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: April 14, 2023
Expiration date: April 14, 2024

Time to complete activity: 1.0 hour

Learner level: Advanced
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explore strategies for mitigating and monitoring drug-related toxicities of novel treatment modalities in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
• Plan for optimal, safe use of antibody-based regimens in R/R DLBCL through pharmacist-led development of guidelines and standard operating procedures

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-23-142-H01-P. The activity is available for CE credit through April 14, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Karen M. Fancher, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose: Consultant for AstraZeneca Pharmaceuticals, LP; G1 Therapeutics; BTG Specialty Pharmaceuticals; Speaker for G1 Therapeutics

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Victoria Nachar, PharmD, BCOP, and Arpita Gandhi, PharmD, BCOP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy Seung, PharmD, BCOP, FHOPA, CHCP; Amy Morris, PharmD; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms